Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (118) clinical trials

Eli Lilly and Company (Lilly) is developing LY3202626, a synthetic small molecule which is a potent inhibitor of β-site amyloid precursor protein (APP)-cleaving enzyme [BACE]1, for the treatment of Alzheimer’s disease (AD). It is hypothesized that inhibition of BACE1 may slow or inhibit the progression of AD. Study I7X-MC-LLCF (LLCF), ...

Phase

Researchers are studying a drug called BAN2401 in people who have early Alzheimer's disease . People with Alzheimer's disease have a buildup of abnormal protein, known as amyloid, in their brains. BAN2401 may reduce the amount of this abnormal protein. The study drug will be given through injection into a ...

Phase

SPRI Clinical Trials of Brooklyn, under the sponsorship of Suven Life Sciences, is currently participating in the clinical evaluation of the safety and effectiveness of an investigational drug in persons with moderate dementia due to Alzheimer’s disease.

Phase

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Phase

NAVIGATE-AD is a 52 week (plus a 4 week follow up visit), double blind study where participants will be randomly assigned (like the flip of a coin) to receive either 1 of 2 doses of study drug (LY32022626) or a placebo (tablet containing no active ingredients, similar to a "sugar ...

Phase

NEUP11-AD2 is a 26 week (plus a 2 week Follow up Visit) double blind study where participants will be randomly assigned (like the flip of a coin) to receive either 1 of 3 doses of study drug (Piromelatine) or a placebo (tablet containing no active ingredients, similar to a sugar ...

Phase

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The ...

Phase

Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in ...

Phase